The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I have also considered that a company maybe doing the due diligence in the background on Accustem with a view to a buyout. They have a strategic partnership with Emeritus DX so they would be my favourites.
We know a buyout is the end goal for the company.
Personally, I would rather wait 2-3 years and get taken over when the market is on a bull run.
It's been 3 years roughly with a product that is supposed to be roughly 30 40 % superior to it's rival. We have a board of directors a c.e.o a c.b.o. a. c.f.o we could even have a u.f.o for all we knowđ Every thing is and has been in place for a while now but only hope to list end of 2024 why the hold up.
Just my thoughts but I think some company is in the back round checking this product out making sure it does exactly what it says on the tin before a buy out or joint venture.
If any body else can think of why there's such a long delay please post. Would love to hear anybody else's thoughtsđ¤
Think they will get bought out before the end of 2024 anyone any ideas what acustem could be worth
Commercialisation end of 2024, Iâll take that.
Not sure itâs a good time to be floating at the moment so Iâll stay patient.
That was 4 months ago. We have had nothing since and their cash runway must have expired now. No cash left surely unless they have got it from elsewhere
Thanks rockz.
looks promising just have to wait a little bit longer
I have said this before, but I believe that Tiziana`s delivery system and Foralumab are 50% of a potential blockbuster drug. TLSA have stated Foralumab is suitable for joint formulation with other drugs. Therefore the Munich conference is exactly the forum to to exchange ideas and pursue partnerships with other drug developers in the CNS field.
Paul the plumber if youâre still on here do you have anything to do with accustem now as well as Tiziana?
Is there an update? Are they going bust? Have they got funding? Are they in talks for a buyout? Whatâs the score?
No main market listing.
No âdual listing off the batâ.
Have we lost all hope of something decent coming to fruition with accustem ?
Sorry bonidel for been stupid but what happens or has happened on the 31th đ¤
31st is fast approaching!
Paul is there an update on accustem? Itâs been over 1000 days since the ex date, almost 3 years and yet still no main market listing.
I cannot understand this share at all.
Thanks indeed Paul, for keeping us updated.
'For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations '
Only up roughly 3.5 % on fantastic news like that.
This company could find a cure for cancer and it still wouldn't move the share price.
Again thanks to everybody who takes time to post information
We live in hope
Thanks for the information Paul much appreciated
Thanks for posting Paul. This is great news for Tiziana and the patients.
After weeks' wait, 86c achieved and I sliced a third. Not much my holding is not large, but, to quote Tesco...
Sorry, nil to say of accustem.
Still no main market listing.
MCAP $8m vs $280m forecast
No updates for months
Will we ever get another update on this?
Surely they are out of cash by nowâŚ
Are we going to lose the lot? Have they got an investor? Have they been loaned another $1m or whatever to keep them plodding on?
Have they got a sale agreed? Is it even worth anything?
Can someone update us? Itâs like 3 years since the EX date at the end of this month